RxDoctor Payments Data

Rachel Allen

Family Medicine · Sabetha, KSNPI 1619400207

Payments from drug & device makers

$582in general payments, 2019–2025

Across 35 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$133
  • Lundbeck LLC$91
  • Novo Nordisk$71
  • Eisai Inc.$60
  • Novartis$49
  • Boston Scientific$37
  • plus $141 from 7 others

What the payments were for

  • Food & beverage$56898%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$582 in reported general payments places this provider in the 50th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$9,210
Medicare patients
59
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$58,182
OzempicSemaglutide29$38,704
MounjaroTirzepatide33$34,129
Bydureon BciseExenatide Microspheres25$20,000
FarxigaDapagliflozin Propanediol27$19,604
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$17,928
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,771
LinzessLinaclotide16$8,528
Breo ElliptaFluticasone/Vilanterol19$8,023
XareltoRivaroxaban29$7,868
NamzaricMemantine Hcl/Donepezil Hcl23$6,017
Fentanyl86$5,473
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$4,358
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc43$4,152
Gabapentin267$3,666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$71$38,70429 claims
AstraZenecaFarxiga, Breztri Aerosphere$133$37,53254 claims
Lilly USA, LLCMounjaro$34$34,12933 claims
AbbVieLinzess, Namzaric$15$14,54539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Sabetha

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →